Farther Finance Advisors LLC Reduces Holdings in AstraZeneca PLC (NASDAQ:AZN)

Farther Finance Advisors LLC cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,401 shares of the company’s stock after selling 208 shares during the quarter. Farther Finance Advisors LLC’s holdings in AstraZeneca were worth $421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the 2nd quarter valued at approximately $26,000. Pathway Financial Advisers LLC bought a new position in AstraZeneca during the 1st quarter valued at approximately $29,000. Hobbs Group Advisors LLC bought a new position in AstraZeneca during the 2nd quarter valued at approximately $35,000. Finally, Versant Capital Management Inc raised its position in AstraZeneca by 1,614.8% during the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after purchasing an additional 436 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock opened at $64.69 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $200.58 billion, a P/E ratio of 31.11, a PEG ratio of 1.32 and a beta of 0.47. The stock’s 50 day moving average is $77.98 and its 200 day moving average is $78.65. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

Wall Street Analyst Weigh In

AZN has been the subject of a number of recent analyst reports. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.